CoChat
Sign Up
Cited by 288Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMenopause: Health Impacts and Treatments

Risk Factors for Dementia

Open access
Chen, Jen-Hau, Lin, Kun-Pei, Chen, Yen-Ching·2009·Journal of the Formosan Medical Association
DOI 10.1016/s0929-6646(09)60402-2
Open this paper in CoChat — free accountOpen PDF

Abstract

Dementia is a complex human disease. The incidence of dementia among the elderly population is rising rapidly worldwide. In the United States, Alzheimer's disease (AD) is the leading type of dementia and was the fifth and eighth leading cause of death in women and men aged > or = 65 years, respectively, in 2003. In Taiwan and many other counties, dementia is a hidden health issue because of its underestimation in the elderly population. In Western countries, the prevalence of AD increases from 1-3% among people aged 60-64 years to 35% among those aged > 85 years. In Taiwan, the prevalence of dementia for people aged > or = 65 years was 2-4% by 2000. Therefore, it is important to identify protective and risk factors for dementia to prevent this disease at an early stage. Several factors are related to dementia, e.g. age, ethnicity, sex, genetic factors, physical activity, smoking, drug use, education level, alcohol consumption, body mass index, comorbidity, and environmental factors. In this review, we focus on studies that have evaluated the association between these factors and the risk of dementia, especially AD and vascular dementia. We also suggest future research directions for researchers in dementia-related fields.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0929-6646(09)60402-2

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Age is the biggest risk factor for dementia.

    “Furthermore, most of the negative attitudes towards aging are related to cognitive abilities of older adults, and these negative attitudes can occur even without any indication of cognitive decline (Cuddy et al., 2005; Nosek et al., 2002; Whitbourne & Seed, 2002), and age is, indeed, the biggest risk factor for dementia (Chen, Lin, & Chen, 2009).”

    From Correlates of dementia-related anxiety: self-perceived dementia risk and ageism (2020) · cites this paper as Chen, Lin, & Chen, 2009

    The Age section says dementia risk increases with age and describes aging as a relatively consistent risk factor across ethnic groups. It does not rank age against other risk factors, so it does not establish that age is the biggest. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 127 · Cited by 288

Part of this paper’s reference list could not be split into single entries.

Research works printed but not linked: 83

  1. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005;53:1-48.
  2. Albert MS. Changing the trajectory of cognitive decline? N Engl J Med 2007;357:502-3.
  3. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44: 181-93.
  4. Liu CK, Tai CT, Lin RT, et al. Epidemiology of dementia in Taiwan. Appl Psychol Res 2000;7:157-69.
  5. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol 2005;62:192-5.
  6. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007;184:69-91.
  7. Wong PC, Cai H, Borchelt DR, et al. Genetically engi- neered mouse models of neurodegenerative diseases. Nat Neurosci 2002;5:633-9.
  8. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo mea- surement of activated microglia in dementia. Lancet 2001; 358:461-7.
  9. Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2005;2:22.
  10. Moechars D, Dewachter I, Lorent K, et al. Early phenotypic changes in transgenic mice that overexpress different mu- tants of amyloid precursor protein in brain. J Biol Chem 1999;274:6483-92.
  11. Hu J, Akama KT, Krafft GA, et al. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 1998;785:195-206.
  12. Lindberg C, Selenica ML, Westlind-Danielsson A, et al. Beta-amyloid protein structure determines the nature of cytokine release from rat microglia. J Mol Neurosci 2005; 27:1-12.
  13. White JA, Manelli AM, Holmberg KH, et al. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 2005;18: 459-65.
  14. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-3.
  15. Gatz M, Fratiglioni L, Johansson B, et al. Complete ascer- tainment of dementia in the Swedish Twin Registry: the HARMONY study. Neurobiol Aging 2005;26:439-47.
  16. Pedersen NL, Gatz M, Berg S, et al. How heritable is Alzheimer's disease late in life? Findings from Swedish twins. Ann Neurol 2004;55:180-5.
  17. Richard F, Amouyel P. Genetic susceptibility factors for Alzheimer's disease. Eur J Pharmacol 2001;412:1-12.
  18. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apo- lipoprotein E: high-avidity binding to beta-amyloid and in- creased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90: 1977-81.
  19. Pastor P, Goate AM. Molecular genetics of Alzheimer's disease. Curr Psychiatry Rep 2004;6:125-33.
  20. Du Y, Dodel RC, Eastwood BJ, et al. Association of an in- terleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 2000;55:480-3.
  21. Hedley R, Hallmayer J, Groth DM, et al. Association of interleukin-1 polymorphisms with Alzheimer's disease in Australia. Ann Neurol 2002;51:795-7.
  22. Nicoll JA, Mrak RE, Graham DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000;47:365-8.
  23. McCusker SM, Curran MD, Dynan KB, et al. Association be- tween polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's dis- ease and vascular dementia: a case-control study. Lancet 2001;357:436-9.
  24. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001;58:1790-2.
  25. Abraham R, Moskvina V, Sims R, et al. A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. BMC Med Genomics 2008;1:44.
  26. Bertram L, Lange C, Mullin K, et al. Genome-wide associ- ation analysis reveals putative Alzheimer's disease suscep- tibility loci in addition to APOE. Am J Hum Genet 2008; 83:623-32.
  27. Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 2009;41:192-8.
  28. Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999;52:78-84.
  29. Bachman DL, Wolf PA, Linn RT, et al. Incidence of demen- tia and probable Alzheimer's disease in a general popula- tion: the Framingham Study. Neurology 1993;43:515-9.
  30. Kawas C, Gray S, Brookmeyer R, et al. Age-specific inci- dence rates of Alzheimer's disease: the Baltimore Longitu- dinal Study of Aging. Neurology 2000;54:2072-7.
  31. Lopez-Pousa S, Vilalta-Franch J, Llinas-Regla J, et al. Incidence of dementia in a rural community in Spain: the Girona cohort study. Neuroepidemiology 2004;23:170-7.
  32. Liu L, Guo XE, Zhou YQ, et al. Prevalence of dementia in China. Dement Geriatr Cogn Disord 2003;15:226-30.
  33. Urakami K, Adachi Y, Takahashi K. A community-based study of parental age at the birth of patients with demen- tia of the Alzheimer type. Arch Neurol 1989;46:38-9.
  34. Corkin S, Growdon JH, Rasmussen SL. Parental age as a risk factor in Alzheimer's disease. Ann Neurol 1983;13:674-6.
  35. Bertram L, Busch R, Spiegl M, et al. Paternal age is a risk factor for Alzheimer disease in the absence of a major gene. Neurogenetics 1998;1:277-80.
  36. Corkin S, Growdon JH, Rasmussen SL. Parental age as a risk factor in Alzheimer's disease. Ann Neurol 1983;13:674-6.
  37. Jouan-Flahault C, Seroussi MC, Colvez A. Absence of a relationship between senile dementia and parental age. A case report survey in Upper Normandy. Rev Epidemiol Sante Publique 1989;37:73-5. [In French]
  38. Ptok U, Papassotiropoulos A, Maier W, et al. Advanced parental age: a risk factor for Alzheimer's disease or de- pression in the elderly? Int Psychogeriatr 2000;12:445-51.
  39. Ruitenberg A, Ott A, van Swieten JC, et al. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001;22:575-80.
  40. Ravaglia G, Forti P, Maioli F, et al. Incidence and etiology of dementia in a large elderly Italian population. Neurology 2005;64:1525-30.
  41. Yaffe K, Barnes D, Nevitt M, et al. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med 2001;161:1703-8.
  42. Barnes DE, Yaffe K, Satariano WA, et al. A longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults. J Am Geriatr Soc 2003;51:459-65.
  43. Karp A, Paillard-Borg S, Wang HX, et al. Mental, physical and social components in leisure activities equally con- tribute to decrease dementia risk. Dement Geriatr Cogn Disord 2006;21:65-73.
  44. Laurin D, Verreault R, Lindsay J, et al. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001;58:498-504.
  45. Abbott RD, White LR, Ross GW, et al. Walking and demen- tia in physically capable elderly men. JAMA 2004;292: 1447-53.
  46. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004;85:1694-704.
  47. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of phys- ical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008;300: 1027-37.
  48. Barnes DE, Whitmer RA, Yaffe K. Physical activity and de- mentia: the need for prevention trials. Exerc Sport Sci Rev 2007;35:24-9.
  49. Podewils LJ, Guallar E, Kuller LH, et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005;161:639-51.
  50. Aggarwal NT, Bienias JL, Bennett DA, et al. The relation of cigarette smoking to incident Alzheimer's disease in a biracial urban community population. Neuroepidemiology 2006;26:140-6.
  51. Merchant C, Tang MX, Albert S, et al. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999;52:1408-12.
  52. Juan D, Zhou DH, Li J, et al. A 2-year follow-up study of cigarette smoking and risk of dementia. Eur J Neurol 2004;11:277-82.
  53. Lagnaoui R, Begaud B, Moore N, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002;55:314-8.
  54. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins re- duce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217-24.
  55. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associ- ated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20.
  56. Forette F, Seux ML, Staessen JA, et al. Prevention of de- mentia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
  57. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163: 1069-75.
  58. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
  59. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994;154:2154-60.
  60. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046-2.
  61. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
  62. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen dur- ing menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
  63. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48: 1517-21.
  64. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-95.
  65. Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal estrogen replacement therapy and risk of AD: a population- based study. Neurology 1999;52: 965-70.
  66. Zandi PP, Carlson MC, Plassman BL, et al. Hormone re- placement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288: 2123-9.
  67. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cogni- tive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
  68. Barrett-Connor E, Kritz-Silverstein D. Estrogen replace- ment therapy and cognitive function in older women. JAMA 1993;269:2637-41.
  69. Matthews K, Cauley J, Yaffe K, et al. Estrogen replace- ment therapy and cognitive decline in older community women. J Am Geriatr Soc 1999;47:518-23.
  70. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti- inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23:159-69.
  71. Wyss-Coray T. Inflammation in Alzheimer disease: driv- ing force, bystander or beneficial response? Nat Med 2006;12:1005-15.
  72. Aisen PS, Schafer KA, Grundman M, et al. Effects of ro- fecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289:2819-26.
  73. Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008;70:17-24.
  74. Scharf JM, Daffner KR. NSAIDs in the prevention of dementia: a Cache-22? Neurology 2007;69:235-6.
  75. ADAPT Research Group. Cardiovascular and cerebrovas- cular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33.
  76. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003;23:7504-9.
  77. Zilka N, Ferencik M, Hulin I. Neuroinflammation in Alzheimer's disease: protector or promoter? Bratisl Lek Listy 2006;107:374-83.
  78. Cobb JL, Wolf PA, Au R, et al. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology 1995;45:1707-12.
  79. Chibnall JT, Eastwood R. Postsecondary education and dementia risk in older Jesuit priests. Int Psychogeriatr 1998;10:359-68.
  80. Shadlen MF, Siscovick D, Fitzpatrick AL, et al. Education, cognitive test scores, and black-white differences in dementia risk. J Am Geriatr Soc 2006;54:898-905.
  81. Karp A, Kareholt I, Qiu C, et al. Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. Am J Epidemiol 2004;159:175-83.
  82. O'Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovas- cular health: the razor-sharp double-edged sword. J Am Coll Cardiol 2007;50:1009-14.
  83. Otsuka M, Yamaguchi K, Ueki A. Similarities and differ- ences between Alzheimer's disease and vascular de- mentia from the viewpoint of nutrition. Ann NY Acad Sci 2002;977:155-61.

Authors
Chen, J.-H., Lin, K.-P., & Chen, Y.-C.
Affiliations
National Taiwan University (TW)
Corresponding author
Chen, Yen-Ching
ORCID
Venue
Journal of the Formosan Medical Association
Publisher
Elsevier BV
Published
2009-10
Volume
108
Issue
10
Pages
754-764
ISSN
0929-6646 (ISSN-L)
DOI
10.1016/s0929-6646(09)60402-2
OpenAlex
W2048970899
Cited by
288
References
127
Citations by year
2026: 8 · 2025: 14 · 2024: 21 · 2023: 32 · 2022: 30 · 2021: 22 · 2020: 20 · 2019: 17 · 2018: 12 · 2017: 12 · 2016: 17 · 2015: 15 · 2014: 17 · 2013: 15 · 2012: 7
FWCI
1.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the Formosan Medical Association (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
dementia, Alzheimer's disease, vascular dementia, risk factors, protective factors, physical activity, smoking, alcohol consumption, body mass index, comorbidities, educational attainment, genetic factors, older adults, dementia prevalence, dementia prevention
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Risk Factors, Socioeconomic Factors, Taiwan, Dementia, Vascular, Incidence, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review